| B33 | Clinical impact of antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analyses of the phase 3 BRIGHTE study | E-poster | ART in highly treatment-experienced people |
| B33 | Aggregating loss to follow-up behavior in Patients Living with HIV: a cluster analysis using unsupervised machine learning algorithm in R | E-poster | ART in highly treatment-experienced people |
| B35 | Comparison of viral replication for the 2-drug regimen (2DR) of dolutegravir/lamivudine (DTG/3TC) versus a 3/4-drug tenofovir alafenamide'based regimen (TBR) in the TANGO study through week 96 | On-demand oral abstract session | Regimen simplification and switch studies |
| B35 | Prevalence of baseline virological risk factors of increased virological failure to CAB+RPV among ARV-naïve patients | On-demand oral abstract session | Regimen simplification and switch studies |
| B35 | APOBEC editing in HIV DNA proviral vif and pol long-reads issued from virologically-suppressed patients included in the ANRS LAMIDOL trial | On-demand oral abstract session | Regimen simplification and switch studies |
| B35 | Switching to the 2-drug regimen of dolutegravir/lamivudine (DTG/3TC) fixed-dose combination (FDC) is non-inferior to continuing a 3-drug regimen through 24 weeks in a randomized clinical trial (SALSA) | Oral abstract session with live Q&A | Regimen simplification and switch studies |
| B35 | Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance | E-poster | Regimen simplification and switch studies |
| B35 | Switch to BIC/FTC/TAF in virally suppressed PLWH: efficacy and tolerability | E-poster | Regimen simplification and switch studies |
| B35 | Co-formulated bictegravir, emtricitabine, and tenofovir alafenamide (BIC/F/TAF) for maintenance of viral suppression in adults with historical virological failure and K65N/R mutation | E-poster | Regimen simplification and switch studies |
| B35 | Switching to bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) in adults aged 65 years or older: week 96 results from an international, Phase 3b, open-label trial | E-poster | Regimen simplification and switch studies |